SEC Form 4 · accession 0001209191-18-038946
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven M. Goldman
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $30.11 | Jun 19, 2018 | A | 10,000 | A | — | Jun 19, 2028 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The shares subject to the option will vest in equal monthly installments over the 12 months commencing on July 19, 2018, provided that the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.